MIF-1

What it is

MIF-1 (Pro-Leu-Gly-NH₂ / Melanostatin / PLG) is a naturally occurring endogenous tripeptide derived from the C-terminal sequence of oxytocin (the Pro-Leu-Gly-NH₂ sequence constitutes the C-terminal tripeptide amide of the oxytocin nonapeptide). It was originally characterized as an inhibitor of MSH (melanocyte-stimulating hormone) release from the pituitary pars intermedia — hence the name Melanocyte-Stimulating Hormone Release-Inhibiting Factor 1 (MIF-1) / Melanostatin. However, its best-characterized and most therapeutically relevant activity is as a positive allosteric modulator (PAM) of the dopamine D2 receptor (D2R) in the central nervous system (PMID 31347842, PMID 10821635). MIF-1 does not directly bind to the D2R orthosteric (dopamine) binding site but instead modulates receptor sensitivity and signaling from an allosteric site. At the biochemical level, MIF-1 and its peptidomimetic analog PAOPA (3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide) increase the proportion of D2R in its high-affinity agonist-binding conformation, confirmed by enhanced [³H]-N-propylapomorphine binding and increased dopamine-stimulated GTPase activity in striatal membranes. MIF-1 also inhibits dopamine-stimulated adenylyl cyclase activity in a dose-dependent manner, consistent with D2R (Gi/o-coupled) signaling modulation. In vivo, MIF-1 activates the striatal dopaminergic system: intracerebroventricular injection (3.5–3500 pmol) dose-dependently increased dopamine disappearance in the nucleus caudatus and globus pallidus (consistent with enhanced dopamine turnover and receptor stimulation), and showed effects on noradrenaline in limbic regions. Behaviorally, MIF-1 reverses reserpine-induced behavioral deficits (decreased body temperature, eyelid drooping, reduced movement) and antagonizes haloperidol-induced catalepsy in rodents — hallmarks of dopaminergic system enhancement. In striatal tissue, intrastriatal MIF-1 potentiates apomorphine-induced stereotypy, further confirming D2R sensitization. In Parkinson's disease-relevant models, PAOPA (a potent PLG analog) demonstrated 100-fold greater potency than parent PLG in 6-OHDA-lesioned rats in the rotational behavior paradigm, and significantly attenuated haloperidol-induced vacuous chewing movements (tardive dyskinesia model). PAOPA also provided superior neuroprotection over PLG in MPTP-treated mice by more effectively sparing striatal dopamine and dopamine metabolite levels. Novel peptidomimetic MIF-1 analogs (compound 6b) have been developed as positive allosteric modulators of D2R with confirmed nanomolar functional activity and favorable safety profiles. Chronic PLG treatment (20 mg/kg IP × 28 days) downregulated heterogeneous nuclear ribonucleoprotein L (hnRNP-L) expression in the striatum (71% reduction) and prefrontal cortex (61% reduction) — suggesting long-term neuroplastic effects.

Class: Endogenous tripeptide neuropeptide / dopamine D2 receptor positive allosteric modulator / oxytocin C-terminal fragment

What it's studied for

• Parkinson's disease and dopaminergic neurodegeneration — neuroprotection and motor symptom modulation Animal studies only
  • 6-OHDA-lesioned rats: MIF-1 peptidomimetic analog A potentiated apomorphine-induced contralateral rotations with ~100-fold greater potency than parent PLG; analog B was 10-fold more potent. Both compounds significantly attenuated haloperidol-induced vacuous chewing movements (tardive dyskinesia model). Bell-shaped dose PMID 17766011 Castellano JM et al. Peptides. 2007.
  • MPTP-treated C57BL/6 mice: PAOPA (PLG peptidomimetic) provided superior neuroprotection vs. parent MIF-1, more effectively sparing striatal dopamine and metabolite levels following MPTP neurotoxin. Mechanism uncertain — either D2R stimulation or reduced oxidative stress through normalized dopamine turnover. Extends PLG PMID 9493876 Marcotte ER et al. Peptides. 1998.
  • Review: MIF-1 improves Parkinson's disease symptoms, attenuates levodopa-related dyskinesias, and reduces tardive dyskinesia manifestations in preliminary findings. MIF-1 partially protects against MPTP-induced nigrostriatal dopamine depletion in mice. Author proposes pineal melatonin augmentation as a complementary me PMID 1979968 Sandyk R et al. Int J Neurosci. 1990.
• Dopamine D2 receptor positive allosteric modulation — neurochemical mechanism Animal studies only
  • Rat striatal membrane preparations: PLG (1 µM) and PAOPA (1 nM) increased N-propylapomorphine-stimulated GTPase activity (D2R high-affinity state marker) and inhibited dopamine-stimulated adenylyl cyclase dose-dependently. Confirms PLG maintains D2R high-affinity conformation through enhanced GTP hydrolysis — the bioch PMID 10821635 Mishra RK et al. Neurosci Lett. 1999.
  • Novel MIF-1 peptidomimetics library (8 compounds): compound 6b significantly enhanced [³H]-N-propylapomorphine D2R binding at nanomolar concentrations (comparable to parent MIF-1). cAMP mobilization confirmed positive allosteric modulator activity. No intrinsic agonism. No cytotoxicity or neurotoxicity up to 100 µM. Su PMID 31347842 Sampaio-Dias IE et al. ACS Chem Neurosci. 2019.
• Tardive dyskinesia — prevention and attenuation Animal studies only
  • Haloperidol-pretreated rats (tardive dyskinesia model): both alpha-MSH and MIF-I increased stereotypic behavior at lowest apomorphine dose (0.125 mg/kg), suggesting weak dopaminergic potentiation. Establishes MIF-1's activity in neuroleptic-sensitized dopamine model, providing rationale for tardive dyskinesia therapeut PMID 6105677 Davis KL et al. Pharmacol Biochem Behav. 1980.
• Striatal dopamine and catecholamine modulation Animal studies only
  • ICV Pro-Leu-GlyNH₂ (3.5–3500 pmol) in male rats: dose-dependently increased dopamine disappearance in nucleus caudatus and globus pallidus (indicating enhanced DA turnover/receptor stimulation); decreased noradrenaline breakdown in limbic regions. Effects paralleled by vasopressin and oxytocin, suggesting shared centra PMID 6150749 van Heuven-Nolsen D et al. Brain Res. 1984.
  • Mice/rats: MIF IP reversed reserpine-induced behavioral deficits (temperature, eyelid drooping, locomotion) and antagonized haloperidol-induced catalepsy. Intrastriatal MIF potentiated apomorphine-induced stereotypy. Homovanillic acid (DA metabolite) changes confirmed dopaminergic activation. Confirms TRH and MIF activ PMID 6140814 Klusha B et al. Acta Physiol Pharmacol Bulg. 1983.
• Neuroplasticity — long-term striatal gene expression changes Animal studies only
  • Chronic PLG treatment (20 mg/kg IP × 28 days) in male rats: ddPCR identified hnRNP-L (heterogeneous nuclear ribonucleoprotein L) as a PLG-regulated gene. Northern blot and Western analysis showed 71% hnRNP-L reduction in striatum and 61% in prefrontal cortex; no change in nucleus accumbens. Suggests long-term PLG treat PMID 12576095 Costain WJ et al. Peptides. 2003.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• Novel MIF-1 peptidomimetic (compound 6b) showed no cytotoxicity or neurotoxicity at up to 100 µM in cell culture assays. As an endogenous tripeptide, intrinsic toxicity is expected to be low, but no human data exists. PMID 31347842
• Chronic PLG (20 mg/kg IP × 28 days) in rats produced significant reductions in hnRNP-L protein in striatum and prefrontal cortex (71% and 61% respectively) — indicates persistent neuroplastic changes with sustained dosing, significance for humans unknown. PMID 12576095
• No adverse events described in any reviewed animal study abstract. All studies involved rodents; no primate or human safety data. PMID 9493876

Contraindications

• No formal contraindications established in reviewed literature. As a dopamine D2 receptor positive allosteric modulator, theoretical caution is warranted in individuals with psychosis-spectrum conditions or those taking antipsychotic D2 receptor antagonists — potential pharmacodynamic interaction. PMID 17766011
• No human clinical trial data exists; compound has not been evaluated for human safety. Use outside supervised research settings is not supported by any evidence base. PMID 31347842